Cargando…
The potential of individualized dosing of ravulizumab to improve patient‐friendliness of paroxysmal nocturnal haemoglobinuria treatment at reduced costs
Ravulizumab is a very expensive complement C5‐inhibitor for the treatment of paroxysmal nocturnal haemoglobinuria, with a fixed‐dosing interval of 8 weeks. For lifelong treatment, a cost‐effective and patient‐friendly dosing strategy is preferred. We therefore explored alternative ravulizumab dosing...
Autores principales: | ter Avest, Mendy, Langemeijer, Saskia M.C., Schols, Saskia E.M., Burger, David M., van de Kar, Nicole C.A.J., Blijlevens, Nicole M.A., Kievit, Wietske, ter Heine, Rob |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359320/ https://www.ncbi.nlm.nih.gov/pubmed/33512711 http://dx.doi.org/10.1111/bcp.14748 |
Ejemplares similares
-
Ravulizumab for paroxysmal nocturnal haemoglobinuria
Publicado: (2022) -
Cholecystectomy in a patient with paroxysmal nocturnal haemoglobinuria undergoing ravulizumab maintenance treatment
por: Moriyama, Mitsuru, et al.
Publicado: (2021) -
Effect of Eculizumab on Iron Metabolism in Transfusion-independent Patients With Paroxysmal Nocturnal Hemoglobinuria
por: Schaap, Charlotte C.M., et al.
Publicado: (2023) -
Paroxysmal nocturnal haemoglobinuria and diabetes mellitus.
por: Andrews, W. J., et al.
Publicado: (1990) -
Coombs-positive Paroxysmal Nocturnal Haemoglobinuria
por: Kalam, Sabrina, et al.
Publicado: (2020)